Laurus Labs Limited LAURUSLABS NIFTY_MIDNSEPHARMA

Q: What is the current share price of Laurus Labs Limited (LAURUSLABS)?

As of 2026-07-15 09:52 IST, Laurus Labs Limited (LAURUSLABS) trades at ₹1,574.70 on NSE. Its 52-week range is ₹788.76 to ₹1,574.70.

Q: What is the market capitalisation of LAURUSLABS?

Laurus Labs Limited (LAURUSLABS) has a market capitalisation of ₹85,011.22 Cr on NSE.

Q: What is the P/E ratio of LAURUSLABS?

LAURUSLABS trades at a trailing price-to-earnings (P/E) ratio of 95.73. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 15.88.

Q: Does LAURUSLABS pay a dividend?

Laurus Labs Limited (LAURUSLABS) currently offers a dividend yield of 0.16%.

Q: What is the return on equity (ROE) of LAURUSLABS?

LAURUSLABS has a return on equity (ROE) of 16.77%. Its return on capital employed (ROCE) is 19.53%.

Q: Is LAURUSLABS a good stock to buy?

This page provides a data-driven analysis of Laurus Labs Limited (LAURUSLABS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.lauruslabs.com

Company Profile ↓

₹1,574.70

+98.81% 1Y

Mkt Cap₹85,011.22 Cr

P/E95.73

P/B15.88

Div. Yield0.16%

52W High₹1,574.70

52W Low₹788.76

Book Value₹98.18

EPS (TTM)₹16.45

Company Overview

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also provides biotechnology services that develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company also offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 16.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 19.5%.

Healthy Margins

Operating margin of 19.4% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of ₹6,721.23 Cr (+22.0% YoY); net profit ₹888.79 Cr.
Trailing 12 Months Year-on-year growth — revenue +22.0%, earnings +148.0%.
5-Year Trend Long-term compounding — revenue CAGR 3.8%, profit CAGR 4.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	3.77%
1 Year:	22.03%

Compounded Profit Growth

5 Years:	4.00%
1 Year:	148.04%

Stock Price Performance

1 Year:	+98.81%
6 Months:	+51.10%
3 Months:	+38.79%
1 Month:	+14.41%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 100% of range

₹788.76 ₹1,574.70

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)68.75 · Neutral

Price Performance

1M+14.41%

3M+38.79%

6M+51.10%

1Y+98.81%

Valuation vs Sector

P/E of 95.73 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

NSE TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 95.7.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

95.73

Industry PE

39.97

Forward P/E

65.70

PEG Ratio

Book Value

₹98.18

Price to Book

15.88

P/S

12.36

EV/EBITDA

48.71

Dividend Yield

0.16%

Growth (CAGR)

Revenue 5Y

3.77%

Profit 5Y

4.00%

Revenue (YoY)

22.03%

Earnings (YoY)

148.04%

Profitability & Returns

ROCE

19.53%

ROE

16.77%

ROA

8.46%

Profit Margin

13.22%

Op Margin

19.44%

Gross Margin

58.88%

EPS (Latest Qtr)

₹5.17

EPS (TTM)

₹16.45

Balance Sheet & Liquidity

Debt/Equity

0.48

Quick Ratio

0.68

Current Ratio

1.33

Debt

₹2,518.48 Cr

Total Assets

₹10,511.19 Cr

Current Assets

₹4,829.21 Cr

Working Capital

₹1,193.78 Cr

Ownership

Promoter Holding

32.04%

Chg in Prom Hold

4.55%

FII / Inst Holding

30.49%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

₹85,011.22 Cr

Total Revenue (TTM)

₹6,721.23 Cr

EBITDA

₹1,822.98 Cr

Free Cash Flow

₹553.55 Cr

Operating Cash Flow

₹1,623.50 Cr

Shares Outstanding

₹53.99 Cr

Gross Margin

58.88%

Payout Ratio

9.73%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA	1,574.70	95.73	₹85,011.22 Cr	0.16%	19.53%	16.77%	3.77%	4.00%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,948.80	40.77	₹4.68 L Cr	0.83%	17.94%	13.74%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	7,315.50	75.61	₹1.94 L Cr	0.44%	18.96%	15.32%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,952.20	87.70	₹1.68 L Cr	0.78%	9.05%	25.79%	13.27%	20.22%
5	APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA	8,981.00	66.51	₹1.29 L Cr	0.23%	19.79%	20.48%	15.33%	33.34%
6	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,440.10	22.07	₹1.16 L Cr	0.90%	14.86%	11.27%	7.23%	11.45%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,137.40	22.71	₹1.14 L Cr	0.09%	19.04%	18.59%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,494.30	21.42	₹1.14 L Cr	0.72%	28.42%	23.76%	19.10%	131.46%
9	MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA	1,099.00	99.82	₹1.07 L Cr	0.18%	12.57%	13.42%	22.37%	9.34%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	1,381.00 Cr	1,182.00 Cr	1,224.00 Cr	1,195.00 Cr	1,440.00 Cr	1,195.00 Cr	-	1,415.05 Cr	1,720.30 Cr	1,569.57 Cr	1,653.00 Cr	1,778.29 Cr	1,811.57 Cr
Cost of Revenue	-	-	-	-	-	-	-	610.15 Cr	782.68 Cr	637.35 Cr	-	694.57 Cr	700.10 Cr
Gross Profit	-	-	-	-	-	-	-	804.90 Cr	937.62 Cr	932.22 Cr	-	1,083.72 Cr	1,111.47 Cr
Operating Expenses	1,095.00 Cr	1,015.00 Cr	1,037.00 Cr	1,014.00 Cr	1,198.00 Cr	1,024.00 Cr	-	625.84 Cr	627.45 Cr	666.93 Cr	1,250.00 Cr	724.13 Cr	721.46 Cr
Operating Income	199.00 Cr	76.00 Cr	95.00 Cr	83.00 Cr	139.00 Cr	65.00 Cr	-	179.06 Cr	310.17 Cr	265.29 Cr	283.00 Cr	359.59 Cr	390.01 Cr
EBITDA	286.00 Cr	167.00 Cr	188.00 Cr	181.00 Cr	241.00 Cr	171.00 Cr	-	294.57 Cr	479.17 Cr	392.56 Cr	403.00 Cr	485.97 Cr	523.91 Cr
Interest Expense	53.00 Cr	39.00 Cr	42.00 Cr	51.00 Cr	50.00 Cr	49.00 Cr	-	57.80 Cr	56.40 Cr	51.50 Cr	40.00 Cr	38.79 Cr	40.44 Cr
Pretax Income	147.00 Cr	41.00 Cr	54.00 Cr	35.00 Cr	107.00 Cr	18.00 Cr	-	130.68 Cr	312.34 Cr	224.22 Cr	270.00 Cr	326.56 Cr	361.37 Cr
Tax Provision	39.69 Cr	12.30 Cr	14.58 Cr	9.45 Cr	32.10 Cr	6.12 Cr	-	40.07 Cr	78.47 Cr	63.14 Cr	75.60 Cr	73.45 Cr	79.46 Cr
Net Income	105.00 Cr	27.00 Cr	37.00 Cr	23.00 Cr	75.00 Cr	13.00 Cr	-	92.30 Cr	233.67 Cr	163.02 Cr	194.00 Cr	251.66 Cr	279.14 Cr
Diluted EPS	1.91	0.46	0.69	0.43	1.40	0.23	0.37	1.71	4.33	3.02	3.61	4.65	5.17

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	1,327.00 Cr	1,778.00 Cr	1,905.00 Cr	2,056.00 Cr	2,292.00 Cr	2,832.00 Cr	4,814.00 Cr	-	6,014.22 Cr	5,001.80 Cr	5,507.86 Cr	6,721.23 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	2,840.71 Cr	2,499.09 Cr	2,539.41 Cr	2,763.59 Cr
Gross Profit	-	-	-	-	-	-	-	-	3,173.51 Cr	2,502.71 Cr	2,968.45 Cr	3,957.64 Cr
Operating Expenses	1,126.00 Cr	1,415.00 Cr	1,497.00 Cr	1,642.00 Cr	1,935.00 Cr	2,266.00 Cr	3,262.00 Cr	-	1,879.24 Cr	2,107.84 Cr	2,343.27 Cr	2,651.27 Cr
Operating Income	138.00 Cr	276.00 Cr	302.00 Cr	289.00 Cr	193.00 Cr	378.00 Cr	1,347.00 Cr	-	1,294.27 Cr	394.87 Cr	625.18 Cr	1,306.37 Cr
EBITDA	200.00 Cr	362.00 Cr	408.00 Cr	414.00 Cr	357.00 Cr	565.00 Cr	1,552.00 Cr	-	1,555.91 Cr	792.70 Cr	1,120.98 Cr	1,822.98 Cr
Interest Expense	106.00 Cr	111.00 Cr	100.00 Cr	80.00 Cr	88.00 Cr	90.00 Cr	68.00 Cr	-	122.89 Cr	171.76 Cr	206.59 Cr	161.05 Cr
Pretax Income	67.00 Cr	169.00 Cr	234.00 Cr	237.00 Cr	120.00 Cr	294.00 Cr	1,301.00 Cr	-	1,108.94 Cr	236.36 Cr	484.29 Cr	1,181.88 Cr
Tax Provision	-1.34 Cr	35.49 Cr	44.46 Cr	68.73 Cr	26.40 Cr	38.22 Cr	312.24 Cr	-	312.30 Cr	68.15 Cr	129.88 Cr	292.03 Cr
Net Income	68.00 Cr	134.00 Cr	190.00 Cr	168.00 Cr	94.00 Cr	255.00 Cr	984.00 Cr	-	790.11 Cr	160.55 Cr	358.32 Cr	888.79 Cr
Diluted EPS	8.81	16.97	3.60	3.16	1.76	4.77	18.33	-	14.64	2.97	6.64	16.45

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	1,888.00 Cr	2,224.00 Cr	2,653.00 Cr	3,017.00 Cr	3,331.00 Cr	3,750.00 Cr	5,751.00 Cr	-	7,660.40 Cr	8,387.03 Cr	9,335.57 Cr	10,511.19 Cr
Current Assets	-	-	-	-	-	-	-	-	3,461.68 Cr	3,834.97 Cr	4,332.32 Cr	4,829.21 Cr
Cash & Equivalents	-	-	-	-	-	-	-	-	45.67 Cr	138.94 Cr	99.54 Cr	112.65 Cr
Inventory	-	-	-	-	-	-	-	-	1,684.81 Cr	1,845.41 Cr	1,936.54 Cr	2,342.16 Cr
Receivables	-	-	-	-	-	-	-	-	1,580.44 Cr	1,662.92 Cr	2,007.16 Cr	2,154.94 Cr
Total Liabilities	-	-	-	-	-	-	-	-	3,611.74 Cr	4,271.46 Cr	4,733.05 Cr	5,079.83 Cr
Current Liabilities	-	-	-	-	-	-	-	-	2,432.26 Cr	3,112.28 Cr	3,539.72 Cr	3,635.43 Cr
Long Term Debt	-	-	-	-	-	-	-	-	761.42 Cr	798.23 Cr	645.58 Cr	611.34 Cr
Total Debt	888.00 Cr	1,094.00 Cr	842.00 Cr	980.00 Cr	1,036.00 Cr	1,079.00 Cr	1,482.00 Cr	-	2,015.09 Cr	2,577.40 Cr	2,763.73 Cr	2,518.48 Cr
Total Equity	656.00 Cr	790.00 Cr	1,331.00 Cr	1,483.00 Cr	1,558.00 Cr	1,770.00 Cr	2,597.00 Cr	-	4,037.53 Cr	4,110.95 Cr	4,472.56 Cr	5,300.06 Cr
Shares Outstanding	-	-	-	-	-	-	-	-	53.87 Cr	53.90 Cr	53.93 Cr	53.99 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-65.00 Cr	182.00 Cr	332.00 Cr	342.00 Cr	298.00 Cr	347.00 Cr	733.00 Cr	-	993.90 Cr	665.69 Cr	601.65 Cr	1,623.50 Cr
Investing Cash Flow	-397.00 Cr	-312.00 Cr	-289.00 Cr	-384.00 Cr	-253.00 Cr	-221.00 Cr	-941.00 Cr	-	-996.06 Cr	-822.42 Cr	-681.72 Cr	-1,088.66 Cr
Financing Cash Flow	486.00 Cr	103.00 Cr	-54.00 Cr	42.00 Cr	-45.00 Cr	-128.00 Cr	255.00 Cr	-	-26.64 Cr	249.83 Cr	39.28 Cr	-524.72 Cr
Capital Expenditure	-382.00 Cr	-326.00 Cr	-277.00 Cr	-391.00 Cr	-254.00 Cr	-222.00 Cr	-684.00 Cr	-	-990.16 Cr	-678.31 Cr	-641.00 Cr	-1,069.95 Cr
Free Cash Flow	-447.00 Cr	-144.00 Cr	55.00 Cr	-49.00 Cr	44.00 Cr	125.00 Cr	49.00 Cr	-	3.74 Cr	-12.62 Cr	-39.35 Cr	553.55 Cr
Net Change in Cash	24.00 Cr	-27.00 Cr	-10.00 Cr	1.00 Cr	-0	-1.00 Cr	47.00 Cr	-	-28.80 Cr	93.10 Cr	-40.79 Cr	10.12 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	52.8%	50.0%	53.9%	58.9%
Operating Margin %	10.4%	15.5%	15.9%	14.1%	8.4%	13.3%	28.0%	-	21.5%	7.9%	11.4%	19.4%
Net Margin %	5.1%	7.5%	10.0%	8.2%	4.1%	9.0%	20.4%	-	13.1%	3.2%	6.5%	13.2%
ROE %	10.4%	17.0%	14.3%	11.3%	6.0%	14.4%	37.9%	-	19.6%	3.9%	8.0%	16.8%
ROCE %	-	-	-	-	-	-	-	-	24.8%	7.5%	10.8%	19.0%

Shareholding Pattern

Insiders

32.04%

Institutions

30.49%

Public Float

44.86%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LAURUSLABS

Google News hu, 04 Jun 2026

How The Laurus Labs (NSEI:LAURUSLABS) Investment Story Is Evolving With A Steady Price Target - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOcFdSYndhMDNna0MzMG84NXFSaGNtUGhRYTNrR0Y3OWp2SmJsNDNEU1F0VFZ2M1dfWFhaTjZCc1N6ajFoRHQxNzdXdVpxMWhELTNvZC03bEduSHlPYTJoZWhMR3JiMF9Wb1U5d1Z6ZTA4UERkbVU0ZmZldEhoTE1IemJqU2V3WURZRC0tSG…

Google News Mon, 04 May 2026

Laurus Labs Limited (NSE:LAURUSLABS) Goes Ex-Dividend Soon - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPZ3djWmhMR2c5R3NoZlU0MUdoLXlYU0VmS25CNmpYRXc5SFdtX1p0TEIyajdpVGRyMmxQZWhTWDVNSmc1NHdrckZKemlheW5ZZi16QkZ5SEh3RVlXaTRsMFp0bkp5cko5WFhFam1yUFNPV0g3c0tOTXhaOF92aEVMazBWazROdDM1Q1IzVV…

Google News ue, 30 Jun 2026

Laurus Labs zooms 53% in Q1FY27; logs sharpest quarterly rally in 5 years - Business Standard

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNaXFwMlRHZVU2TjNMRWE1QVZJWkUwSHdMbmVFR1hEaENIb003dHF4UjJCWmo2UWhkV2VGU3N3M1lXelE3YTIwSE5sSDQwR1J3aEZfc2h2OTNBdGlQall4VzNNUTA2c0VVbDZFWmktTHpUd2pVcC1sRGNYMkRsRmdNWENUWkVrSFY4eW1Gbn…

Google News Fri, 26 Jun 2026

Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improve - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNbVB0XzBYNTk2ZnFpb2E3Q1hib2hKX0ZROWIzcFYwMzhHS3ZSMnd5TDVlUS1qUW1JRmxmMXlWR0pUQWFsUjJTeDA0SlNXVkRjckhpbkNmM0M5ckNDWHY1Rm5nZ29oYkN4cElqVks3UlROcVdkTUJCd0tuWnJCM1lVZzAtc2pWWV9uOHJvSk…

Google News ue, 16 Jun 2026

HOT STOCKS: WABAG, VARROC, GNFC, EDELWEISS, MGL Lead Gainers | SANSERA, NATIONALUM Among Top Losers | TIMKEN, SCHAEFFLER, 3MINDIA Close Above 50-SMA; GICRE, LAURUSLABS, NEULANDLAB Near Key Averages - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMivAJBVV95cUxPc2NfcWJrQkU3VnMxRzNNRHVJeVh3MnFfSUo1Qk45TzZGSDRFQ0E4bEhvM1dPT3BTYVppNEk1eTJFcVI2MjVGUzIxNm5TUWFidV8yS1FibmY2TWFVY21IMERVR291UXpndVlDR2FjQ0c0YXFzbFhHV0duMmEwc1FmV2pLbUJIN1lfd0dvQk…

Google News Wed, 08 Apr 2026

Trade Spotlight: How should you trade Laurus Labs, Schneider Electric, Welspun Corp, DCB Bank, Tech... - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxQSVhUY3BfQlA3VVBwaDZqb01nd0libUxITHNNOHctUFpxTkVUM1IzQU9ZaVY0d0JjMlEyR0NBS3JGQ2FWRjdQaDloZm1BajdHOFdSME5MNDBqYXNGbEtIRVhvZW54RW91R2FNTUlqazdGUTNuSlRjYmZIbW1YZFIzX01UbHJEdGppSDlkdH…

LAURUSLABS — Frequently Asked Questions

What is the current share price of Laurus Labs Limited (LAURUSLABS)?

As of 2026-07-15 09:52 IST, Laurus Labs Limited (LAURUSLABS) trades at ₹1,574.70 on NSE. Its 52-week range is ₹788.76 to ₹1,574.70.

What is the market capitalisation of LAURUSLABS?

Laurus Labs Limited (LAURUSLABS) has a market capitalisation of ₹85,011.22 Cr on NSE.

What is the P/E ratio of LAURUSLABS?

LAURUSLABS trades at a trailing price-to-earnings (P/E) ratio of 95.73. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 15.88.

Does LAURUSLABS pay a dividend?

Laurus Labs Limited (LAURUSLABS) currently offers a dividend yield of 0.16%.

What is the return on equity (ROE) of LAURUSLABS?

LAURUSLABS has a return on equity (ROE) of 16.77%. Its return on capital employed (ROCE) is 19.53%.

Is LAURUSLABS a good stock to buy?

This page provides a data-driven analysis of Laurus Labs Limited (LAURUSLABS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks

Laurus Labs Limited LAURUSLABS NIFTY_MIDNSEPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

How The Laurus Labs (NSEI:LAURUSLABS) Investment Story Is Evolving With A Steady Price Target - Yahoo Finance

Laurus Labs Limited (NSE:LAURUSLABS) Goes Ex-Dividend Soon - simplywall.st

Laurus Labs zooms 53% in Q1FY27; logs sharpest quarterly rally in 5 years - Business Standard

Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improve - The Economic Times

HOT STOCKS: WABAG, VARROC, GNFC, EDELWEISS, MGL Lead Gainers | SANSERA, NATIONALUM Among Top Losers | TIMKEN, SCHAEFFLER, 3MINDIA Close Above 50-SMA; GICRE, LAURUSLABS, NEULANDLAB Near Key Averages - MarketSmith India

Trade Spotlight: How should you trade Laurus Labs, Schneider Electric, Welspun Corp, DCB Bank, Tech... - Moneycontrol.com

LAURUSLABS — Frequently Asked Questions

What is the current share price of Laurus Labs Limited (LAURUSLABS)?

What is the market capitalisation of LAURUSLABS?

What is the P/E ratio of LAURUSLABS?

Does LAURUSLABS pay a dividend?

What is the return on equity (ROE) of LAURUSLABS?

Is LAURUSLABS a good stock to buy?

Explore More